Reports - CD Antigen Cancer Therapy Market
HealthcareCD Antigen Cancer Therapy Market
CD Antigen Cancer Therapy Market Size & Share | Growth Analysis 2035 by Type of CD Antigen Targeted (CD19, CD20, CD30, CD33, CD38, CD70, Other Types) by Therapy Type (Monoclonal Antibodies (mAbs), Antibody-Drug Conjugates (ADCs), Chimeric Antigen Receptor (CAR) T-cell Therapy, Bi-specific T-cell Engagers (BiTEs), Radioimmunotherapy, Immunotoxins) by Cancer Type (Leukemia, Lymphoma, Multiple Myeloma, Breast Cancer, Lung Cancer, Prostate Cancer, Other Cancer Types) by End User (Hospitals, Specialty Clinics, Cancer Treatment Centers, Research Institutes) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global CD Antigen Cancer Therapy Market - Segment Analysis
1. Overview
2. Global CD Antigen Cancer Therapy Market, 2021 - 2035 (USD Million)
3. Global CD Antigen Cancer Therapy Market - by Type of CD Antigen Targeted
3.1. By CD19
3.2. By CD20
3.3. By CD30
3.4. By CD33
3.5. By CD38
3.6. By CD70
3.7. By Other Types
4. Global CD Antigen Cancer Therapy Market - by Therapy Type
4.1. By Monoclonal Antibodies (mAbs)
4.2. By Antibody-Drug Conjugates (ADCs)
4.3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
4.4. By Bi-specific T-cell Engagers (BiTEs)
4.5. By Radioimmunotherapy
4.6. By Immunotoxins
5. Global CD Antigen Cancer Therapy Market - by Cancer Type
5.1. By Leukemia
5.2. By Lymphoma
5.3. By Multiple Myeloma
5.4. By Breast Cancer
5.5. By Lung Cancer
5.6. By Prostate Cancer
5.7. By Other Cancer Types
6. Global CD Antigen Cancer Therapy Market - by End User
6.1. By Hospitals
6.2. By Specialty Clinics
6.3. By Cancer Treatment Centers
6.4. By Research Institutes
7. Global CD Antigen Cancer Therapy Market - by region
7.1. North America
7.2. Europe
7.3. Asia Pacific
7.4. Latin America
7.5. Middle East & Africa
8. Market comparative analysis
Chapter 4 North America CD Antigen Cancer Therapy Market - Segment Analysis
1. Overview
2. North America CD Antigen Cancer Therapy Market, 2021 - 2035 (USD Million)
3. North America CD Antigen Cancer Therapy Market - by Type of CD Antigen Targeted
3.1. By CD19
3.2. By CD20
3.3. By CD30
3.4. By CD33
3.5. By CD38
3.6. By CD70
3.7. By Other Types
4. North America CD Antigen Cancer Therapy Market - by Therapy Type
4.1. By Monoclonal Antibodies (mAbs)
4.2. By Antibody-Drug Conjugates (ADCs)
4.3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
4.4. By Bi-specific T-cell Engagers (BiTEs)
4.5. By Radioimmunotherapy
4.6. By Immunotoxins
5. North America CD Antigen Cancer Therapy Market - by Cancer Type
5.1. By Leukemia
5.2. By Lymphoma
5.3. By Multiple Myeloma
5.4. By Breast Cancer
5.5. By Lung Cancer
5.6. By Prostate Cancer
5.7. By Other Cancer Types
6. North America CD Antigen Cancer Therapy Market - by End User
6.1. By Hospitals
6.2. By Specialty Clinics
6.3. By Cancer Treatment Centers
6.4. By Research Institutes
Chapter 5 Europe CD Antigen Cancer Therapy Market - Segment Analysis
1. Overview
2. Europe CD Antigen Cancer Therapy Market, 2021 - 2035 (USD Million)
3. Europe CD Antigen Cancer Therapy Market - by Type of CD Antigen Targeted
3.1. By CD19
3.2. By CD20
3.3. By CD30
3.4. By CD33
3.5. By CD38
3.6. By CD70
3.7. By Other Types
4. Europe CD Antigen Cancer Therapy Market - by Therapy Type
4.1. By Monoclonal Antibodies (mAbs)
4.2. By Antibody-Drug Conjugates (ADCs)
4.3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
4.4. By Bi-specific T-cell Engagers (BiTEs)
4.5. By Radioimmunotherapy
4.6. By Immunotoxins
5. Europe CD Antigen Cancer Therapy Market - by Cancer Type
5.1. By Leukemia
5.2. By Lymphoma
5.3. By Multiple Myeloma
5.4. By Breast Cancer
5.5. By Lung Cancer
5.6. By Prostate Cancer
5.7. By Other Cancer Types
6. Europe CD Antigen Cancer Therapy Market - by End User
6.1. By Hospitals
6.2. By Specialty Clinics
6.3. By Cancer Treatment Centers
6.4. By Research Institutes
Chapter 6 Asia Pacific CD Antigen Cancer Therapy Market - Segment Analysis
1. Overview
2. Asia Pacific CD Antigen Cancer Therapy Market, 2021 - 2035 (USD Million)
3. Asia Pacific CD Antigen Cancer Therapy Market - by Type of CD Antigen Targeted
3.1. By CD19
3.2. By CD20
3.3. By CD30
3.4. By CD33
3.5. By CD38
3.6. By CD70
3.7. By Other Types
4. Asia Pacific CD Antigen Cancer Therapy Market - by Therapy Type
4.1. By Monoclonal Antibodies (mAbs)
4.2. By Antibody-Drug Conjugates (ADCs)
4.3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
4.4. By Bi-specific T-cell Engagers (BiTEs)
4.5. By Radioimmunotherapy
4.6. By Immunotoxins
5. Asia Pacific CD Antigen Cancer Therapy Market - by Cancer Type
5.1. By Leukemia
5.2. By Lymphoma
5.3. By Multiple Myeloma
5.4. By Breast Cancer
5.5. By Lung Cancer
5.6. By Prostate Cancer
5.7. By Other Cancer Types
6. Asia Pacific CD Antigen Cancer Therapy Market - by End User
6.1. By Hospitals
6.2. By Specialty Clinics
6.3. By Cancer Treatment Centers
6.4. By Research Institutes
Chapter 7 Latin America CD Antigen Cancer Therapy Market - Segment Analysis
1. Overview
2. Latin America CD Antigen Cancer Therapy Market, 2021 - 2035 (USD Million)
3. Latin America CD Antigen Cancer Therapy Market - by Type of CD Antigen Targeted
3.1. By CD19
3.2. By CD20
3.3. By CD30
3.4. By CD33
3.5. By CD38
3.6. By CD70
3.7. By Other Types
4. Latin America CD Antigen Cancer Therapy Market - by Therapy Type
4.1. By Monoclonal Antibodies (mAbs)
4.2. By Antibody-Drug Conjugates (ADCs)
4.3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
4.4. By Bi-specific T-cell Engagers (BiTEs)
4.5. By Radioimmunotherapy
4.6. By Immunotoxins
5. Latin America CD Antigen Cancer Therapy Market - by Cancer Type
5.1. By Leukemia
5.2. By Lymphoma
5.3. By Multiple Myeloma
5.4. By Breast Cancer
5.5. By Lung Cancer
5.6. By Prostate Cancer
5.7. By Other Cancer Types
6. Latin America CD Antigen Cancer Therapy Market - by End User
6.1. By Hospitals
6.2. By Specialty Clinics
6.3. By Cancer Treatment Centers
6.4. By Research Institutes
Chapter 8 Middle East & Africa CD Antigen Cancer Therapy Market - Segment Analysis
1. Overview
2. Middle East & Africa CD Antigen Cancer Therapy Market, 2021 - 2035 (USD Million)
3. Middle East & Africa CD Antigen Cancer Therapy Market - by Type of CD Antigen Targeted
3.1. By CD19
3.2. By CD20
3.3. By CD30
3.4. By CD33
3.5. By CD38
3.6. By CD70
3.7. By Other Types
4. Middle East & Africa CD Antigen Cancer Therapy Market - by Therapy Type
4.1. By Monoclonal Antibodies (mAbs)
4.2. By Antibody-Drug Conjugates (ADCs)
4.3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
4.4. By Bi-specific T-cell Engagers (BiTEs)
4.5. By Radioimmunotherapy
4.6. By Immunotoxins
5. Middle East & Africa CD Antigen Cancer Therapy Market - by Cancer Type
5.1. By Leukemia
5.2. By Lymphoma
5.3. By Multiple Myeloma
5.4. By Breast Cancer
5.5. By Lung Cancer
5.6. By Prostate Cancer
5.7. By Other Cancer Types
6. Middle East & Africa CD Antigen Cancer Therapy Market - by End User
6.1. By Hospitals
6.2. By Specialty Clinics
6.3. By Cancer Treatment Centers
6.4. By Research Institutes
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. Merck & Co. Inc. (U.S.)
2. Johnson & Johnson Inc. (U.S.)
3. Amgen Inc. (U.S.)
4. AbbVie Inc. (U.S.)
5. Novartis AG (Switzerland)
6. Roche Holdings AG (Switzerland)
7. Bristol Myers Squibb Company (U.S.)
8. Biogen Inc. (U.S.)
9. Celgene Corp. (U.S.)
10. Genmab A/S (Denmark)
11. Immunomedics Inc. (U.S.)
12. Gilead Sciences Inc. (U.S.)
13. AstraZeneca PLC (UK)
14. Takeda Pharmaceutical Company Ltd. (Japan)
15. Seattle Genetics Inc. (U.S.)
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By